SH consensus summary
Vara Research Siemens Healthineers Pre FY 2021 Earnings Estimates as of October 26th, 2021
Q4 2020 FY 2020 Q4 2021 E FY 2021 E
Revenue
- Number of Estimates 14 14
- Highest 5,168 18,001
- Consensus 3,876 14,460 5,046 17,879
- Median 5,050 17,883
- Lowest 4,841 17,674
Comparable growth rate (in %)
- Number of Estimates 12 13
- Highest 12.6 19.7
- Consensus -2.0 -0.2 10.6 18.3
- Median 10.9 18.2
- Lowest 8.4 17.0
R&D Expenses
- Number of Estimates 13 13
- Highest -343 -1,406
- Consensus -340 -1,342 -454 -1,517
- Median -423 -1,486
- Lowest -602 -1,665
D&A
- Number of Estimates 14 14
- Highest -224 -978
- Consensus -215 -815 -396 -1,150
- Median -394 -1,148
- Lowest -587 -1,341
Adjusted EBIT (SHS definition)
- Number of Estimates 14 14
- Highest 982 3,331
- Consensus 631 2,248 898 3,247
- Median 905 3,254
- Lowest 798 3,147
Amortization of intangible assets acquired in business combinations
- Number of Estimates 13 13
- Highest -109 -350
- Consensus -39 -168 -187 -428
- Median -179 -420
- Lowest -229 -470
Severance charges
- Number of Estimates 13 13
- Highest -1 -50
- Consensus -22 -65 -20 -69
- Median -16 -65
- Lowest -63 -112
Acquisition-related costs
- Number of Estimates 12 12
- Highest 9 -100
- Consensus -11 -34 -83 -192
- Median -74 -183
- Lowest -164 -273
Financial income, net
- Number of Estimates 14 14
- Highest 47 -95
- Consensus -10 -27 -25 -167
- Median -21 -163
- Lowest -95 -237
Tax expense
- Number of Estimates 14 14
- Highest -111 -640
- Consensus -118 -532 -157 -686
- Median -167 -696
- Lowest -194 -723
Minorities
- Number of Estimates 12 12
- Highest 2 -12
- Consensus -4 -12 -4 -18
- Median -4 -18
- Lowest -6 -20
Reported net income attr. to shareholder
- Number of Estimates 14 14
- Highest 543 1,808
- Consensus 428 1,411 417 1,682
- Median 426 1,691
- Lowest 295 1,560
Number of outstanding shares
- Number of Estimates 14 14
- Highest 1,128 1,108
- Consensus 1,011 1,002 1,127 1,102
- Median 1,128 1,102
- Lowest 1,124 1,100
EPS reported (in EUR)
- Number of Estimates 14 14
- Highest 0.48 1.64
- Consensus 0.42 1.41 0.37 1.53
- Median 0.37 1.53
- Lowest 0.26 1.42
Adjusted EPS (in EUR)
- Number of Estimates 13 13
- Highest 0.61 2.10
- Consensus 0.48 1.61 0.56 2.05
- Median 0.56 2.05
- Lowest 0.51 2.00
DPS (in EUR)
- Number of Estimates 0 13
- Highest - 1.22
- Consensus - 0.80 - 0.89
- Median - 0.88
- Lowest - 0.76
Segment estimates
Imaging, Revenue
- Number of Estimates 14 14
- Highest 2,746 9,809
- Consensus 2,447 9,090 2,645 9,708
- Median 2,663 9,726
- Lowest 2,387 9,450
Imaging, Comparable growth rate (in %)
- Number of Estimates 11 13
- Highest 10.8 11.9
- Consensus -1.7 1.6 9.1 10.7
- Median 9.0 10.7
- Lowest 7.0 10.0
Imaging, Adj. EBIT (SHS definition)
- Number of Estimates 14 14
- Highest 665 2,136
- Consensus 551 1,916 642 2,113
- Median 647 2,118
- Lowest 597 2,068
Diagnostics, Revenue
- Number of Estimates 14 14
- Highest 1,267 5,407
- Consensus 1,038 3,924 1,162 5,302
- Median 1,182 5,322
- Lowest 1,059 5,199
Diagnostics, Comparable growth rate (in %)
- Number of Estimates 11 13
- Highest 18.1 42.0
- Consensus -1.0 -4.2 12.5 39.3
- Median 15.0 40.4
- Lowest 5.0 35.0
Diagnostics, Adj. EBIT (SHS definition)
- Number of Estimates 14 14
- Highest 140 768
- Consensus 8 74 79 707
- Median 80 708
- Lowest 42 670
therein revenue from rapid COVID-19 antigen test
- Number of Estimates 5 5
- Highest 130 1,050
- Consensus - - 104 1,024
- Median 100 1,020
- Lowest 80 1,000
therein adj. EBIT from rapid COVID-19 antigen tests
- Number of Estimates 0 1
- Highest - 434.0
- Consensus - - - 434.0
- Median - 434.0
- Lowest - 434.0
Advanced Therapies, Revenue
- Number of Estimates 14 14
- Highest 493 1,710
- Consensus 432 1,628 481 1,698
- Median 484 1,701
- Lowest 449 1,666
Advanced Therapies, Comparable growth rate (in %)
- Number of Estimates 11 13
- Highest 14.5 9.0
- Consensus -6.4 1.1 11.7 7.9
- Median 12.1 8.0
- Lowest 5.0 6.1
Advanced Therapies, Adj. EBIT (SHS definition)
- Number of Estimates 14 14
- Highest 96.0 269.0
- Consensus 83.0 308.0 80.5 253.5
- Median 80.6 253.6
- Lowest 57.0 230.0
Varian, Revenue
- Number of Estimates 14 14
- Highest 809 1,400
- Consensus - - 767 1,358
- Median 766 1,357
- Lowest 671 1,262
Varian, Comparable growth rate (in %
- Number of Estimates 0
- Highest -
- Consensus - - - -
- Median -
- Lowest -
Varian, Adj. EBIT (SHS definition)
- Number of Estimates 14 14
- Highest 129.0 227.0
- Consensus - - 118.8 216.8
- Median 117.9 215.9
- Lowest 107.0 205.0
Others
Economic net debt (SHS definition)
- Number of Estimates 0 15
- Highest - 15,845
- Consensus - 2,605 - 13,170
- Median - 12,957
- Lowest - 11,570
Change in operating net working capital
- Number of Estimates 0 10
- Highest - 897
- Consensus - -148 - -157
- Median - -14
- Lowest - -1,096
Capex
- Number of Estimates 0 13
- Highest - -617
- Consensus - -557 - -748
- Median - -693
- Lowest - -1,202
Free Cash Flow (SHS definition)
- Number of Estimates 0 13
- Highest - 3,984
- Consensus - 1,371 - 2,064
- Median - 1,986
- Lowest - 1,208
USD assumption
- Number of Estimates 0 5
- Highest - 1.20
- Consensus - 1.20
- Median - 1.20
- Lowest - 1.19
WACC used for DCF
- Number of Estimates 0 5
- Highest - 8.0
- Consensus - 6.7
- Median - 7.0
- Lowest - 5.0
This report was prepared by Vara Research GmbH for informational purposes only and is not intended to provide investment advice. It is based on an evaluation of past and an estimation of future earnings and performance of the relevant company by various market analysts. Owing to their subjective character, such estimates and forecasts cannot be independently verified. Despite careful review, Vara Research GmbH cannot provide any guarantee, assurance or warranty as to completeness or accuracy; responsibility or liability is therefore excluded. This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.

Attachments

  • Original document
  • Permalink

Disclaimer

Siemens Healthineers AG published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 07:30:06 UTC.